MD2852C2 - Use of budesonide for treatment of resistant ascites to pacients with hepatic cirrhosis - Google Patents
Use of budesonide for treatment of resistant ascites to pacients with hepatic cirrhosis Download PDFInfo
- Publication number
- MD2852C2 MD2852C2 MDA20050089A MD20050089A MD2852C2 MD 2852 C2 MD2852 C2 MD 2852C2 MD A20050089 A MDA20050089 A MD A20050089A MD 20050089 A MD20050089 A MD 20050089A MD 2852 C2 MD2852 C2 MD 2852C2
- Authority
- MD
- Moldova
- Prior art keywords
- budesonide
- treatment
- hepatic cirrhosis
- pacients
- resistant ascites
- Prior art date
Links
- 206010003445 Ascites Diseases 0.000 title abstract 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 title abstract 2
- 229960004436 budesonide Drugs 0.000 title abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 title abstract 2
- 210000000683 abdominal cavity Anatomy 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 210000003200 peritoneal cavity Anatomy 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention refers to medicine, in particular to hepatology.Summary of the invention consists in the use of budesonide for treatment of resistant ascites to patients with decompensated hepatic cirrhosis.The result of the invention consists in diminishing the regional chronic inflammatory process by decreasing the permeability of the vascular wall and the liquid transudation into the interstitial space of the abdominal cavity organs and prevents its accumulation into the peritoneal cavity, which leads to the formation of the resistant ascites.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20050089A MD2852C2 (en) | 2005-03-28 | 2005-03-28 | Use of budesonide for treatment of resistant ascites to pacients with hepatic cirrhosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20050089A MD2852C2 (en) | 2005-03-28 | 2005-03-28 | Use of budesonide for treatment of resistant ascites to pacients with hepatic cirrhosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD2852B1 MD2852B1 (en) | 2005-09-30 |
| MD2852C2 true MD2852C2 (en) | 2006-04-30 |
Family
ID=35057532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20050089A MD2852C2 (en) | 2005-03-28 | 2005-03-28 | Use of budesonide for treatment of resistant ascites to pacients with hepatic cirrhosis |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD2852C2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742612A1 (en) * | 1997-09-26 | 1999-04-01 | Falk Pharma Gmbh | Budesonide for the treatment of cholestatic liver diseases |
| WO1999039699A1 (en) * | 1998-02-09 | 1999-08-12 | Rtp Pharma, Inc. | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
-
2005
- 2005-03-28 MD MDA20050089A patent/MD2852C2/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742612A1 (en) * | 1997-09-26 | 1999-04-01 | Falk Pharma Gmbh | Budesonide for the treatment of cholestatic liver diseases |
| WO1999039699A1 (en) * | 1998-02-09 | 1999-08-12 | Rtp Pharma, Inc. | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
Non-Patent Citations (1)
| Title |
|---|
| Spencer C., Mc. Tavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs, 1995, vol. 50, p. 854-872 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD2852B1 (en) | 2005-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1043I1 (en) | USE OF FERRIC CITRATE IN THE TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE | |
| EP2760371A4 (en) | STRUCTURES, METHODS AND SYSTEMS FOR TRANSCATHTHER VENTRICULAR RECONSTRUCTION FOR THE TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER CONDITIONS | |
| TR201818927T4 (en) | Improvement in Catheters | |
| SG11201504463SA (en) | Combination double-barreled and debranching stent grafts | |
| EP3687394A4 (en) | DETERMINING THE LOCATION OF A CATHETER IN PEDIATRIC PATIENTS | |
| PH12018502593A1 (en) | Combinations of linagliptin and metformin | |
| MX2015013944A (en) | Kinase inhibitor. | |
| EP1662965A4 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF BREAST CANCER WITH MORINDA CITRIFLOLIA AND METHYLSULFONYLMETHANE | |
| WO2013022567A3 (en) | Vascular filter | |
| EP2182978A4 (en) | Tissue kallikrein for the treatment of diseases associated with amyloid protein | |
| FR3005564B1 (en) | INSTRUMENT FOR USE IN MODIFYING THE VOLUME OF THE STOMACH OF A PATIENT. | |
| EP2148675A4 (en) | ANTICANCER DRUG FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| FR2919060B1 (en) | METHOD OF DETERMINING EZRINE FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER | |
| EP4279925A3 (en) | Dulaglutide for the treatment of chronic kidney disease | |
| JP2010209101A5 (en) | ||
| MX2015001508A (en) | The use of antithrombin in extracorporeal membrane oxygenation. | |
| EP2185162A4 (en) | Polymer therapy for the treatment of chronic microvascular diseases | |
| WO2007023154A3 (en) | Iron (iii) complex compounds for treating iron deficiency in patients with chronic inflammatory intestinal diseases | |
| de Franciscis et al. | Matrix metalloproteinases and endothelial dysfunction: the search for new prognostic markers and for new therapeutic targets for vascular wall imbalance | |
| EP2170351A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES ASSOCIATED WITH ANGIOGENESIS | |
| EP2470217A4 (en) | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER | |
| EP2455079A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES COMPRISING COLFORSIN DAROPATE | |
| EP1889618A4 (en) | COMBINED MEDICATION FOR THE TREATMENT OF DIABETES | |
| MD2852B1 (en) | Use of budesonide for treatment of resistant ascites to pacients with hepatic cirrhosis | |
| EP2136820A4 (en) | TARGET FOR THE TREATMENT AND / OR DIAGNOSIS OF BREAST CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |